159 related articles for article (PubMed ID: 35381095)
1. Imeglimin: a new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes.
Nowak M; Grzeszczak W
Endokrynol Pol; 2022; 73(2):361-370. PubMed ID: 35381095
[TBL] [Abstract][Full Text] [Related]
2. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
Pirags V; Lebovitz H; Fouqueray P
Diabetes Obes Metab; 2012 Sep; 14(9):852-8. PubMed ID: 22519919
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
Johansson KS; Brønden A; Knop FK; Christensen MB
Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Reilhac C; Dubourg J; Thang C; Grouin JM; Fouqueray P; Watada H
Diabetes Obes Metab; 2022 May; 24(5):838-848. PubMed ID: 34984815
[TBL] [Abstract][Full Text] [Related]
5. Protective Effects of Imeglimin and Metformin Combination Therapy on β-Cells in db/db Male Mice.
Nishiyama K; Ono M; Tsuno T; Inoue R; Fukunaka A; Okuyama T; Kyohara M; Togashi Y; Fukushima S; Atsumi T; Sato A; Tsurumoto A; Sakai C; Fujitani Y; Terauchi Y; Ito S; Shirakawa J
Endocrinology; 2023 Jun; 164(8):. PubMed ID: 37314160
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
Abdelhaleem IA; Salamah HM; Alsabbagh FA; Eid AM; Hussien HM; Mohamed NI; Ebada MA
Diabetes Metab Syndr; 2021; 15(6):102323. PubMed ID: 34717136
[TBL] [Abstract][Full Text] [Related]
7. Imeglimin: Current Development and Future Potential in Type 2 Diabetes.
Konkwo C; Perry RJ
Drugs; 2021 Feb; 81(2):185-190. PubMed ID: 33247829
[TBL] [Abstract][Full Text] [Related]
8. Imeglimin: the New Kid on the Block.
Shrestha SC; Gupta S
Curr Diab Rep; 2024 Jan; 24(1):13-18. PubMed ID: 38051432
[TBL] [Abstract][Full Text] [Related]
9. Exploring new mechanisms of Imeglimin in diabetes treatment: Amelioration of mitochondrial dysfunction.
Li Y; Lou N; Liu X; Zhuang X; Chen S
Biomed Pharmacother; 2024 Jun; 175():116755. PubMed ID: 38772155
[TBL] [Abstract][Full Text] [Related]
10. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.
Vuylsteke V; Chastain LM; Maggu GA; Brown C
Drugs R D; 2015 Sep; 15(3):227-32. PubMed ID: 26254210
[TBL] [Abstract][Full Text] [Related]
11. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
13. Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects.
Fouqueray P; Perrimond-Dauchy S; Bolze S
Clin Pharmacokinet; 2020 Oct; 59(10):1261-1271. PubMed ID: 32270440
[TBL] [Abstract][Full Text] [Related]
14. Imeglimin: A New Promising and Effective Weapon in the Treatment of Type 2 Diabetes.
Doupis J; Baris N; Avramidis K
touchREV Endocrinol; 2021 Nov; 17(2):88-91. PubMed ID: 35118453
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
Theurey P; Thang C; Pirags V; Mari A; Pacini G; Bolze S; Hallakou-Bozec S; Fouqueray P
Endocrinol Diabetes Metab; 2022 Nov; 5(6):e371. PubMed ID: 36239048
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
Dubourg J; Fouqueray P; Thang C; Grouin JM; Ueki K
Diabetes Care; 2021 Apr; 44(4):952-959. PubMed ID: 33574125
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Fouqueray P; Pirags V; Inzucchi SE; Bailey CJ; Schernthaner G; Diamant M; Lebovitz HE
Diabetes Care; 2013 Mar; 36(3):565-8. PubMed ID: 23160726
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2023 Feb; 17(2):102710. PubMed ID: 36702046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
